Financial Performance - The company's operating revenue for Q3 2023 reached ¥84,819,369.39, representing a year-on-year increase of 21.89%[2] - Net profit attributable to shareholders was ¥35,575,818.84, a significant increase of 1,103.79% compared to the same period last year[2] - The basic earnings per share for Q3 2023 was ¥0.0281, reflecting a remarkable growth of 902.86% year-on-year[2] - Operating profit for Q3 2023 was CNY 31,435,041.65, a significant recovery from a loss of CNY 16,374,580.05 in Q3 2022[24] - The net profit for Q3 2023 was ¥20,712,279.01, a significant improvement from a net loss of ¥19,662,576.32 in the same period last year[25] - The net profit attributable to the parent company's shareholders was ¥23,932,124.50, compared to a loss of ¥15,145,520.13 in Q3 2022[25] - The total comprehensive income for the period was ¥20,754,880.99, recovering from a loss of ¥19,662,360.44 in the previous year[25] Assets and Liabilities - Total assets as of September 30, 2023, amounted to ¥1,483,340,166.69, up 140.70% from the end of the previous year[3] - The company's total assets as of Q3 2023 were CNY 1,483,340,166.69, a substantial increase from CNY 616,248,544.88 at the end of Q3 2022[21] - Total liabilities for Q3 2023 were CNY 447,041,466.92, compared to CNY 201,412,272.64 in Q3 2022, indicating a year-over-year increase of 121.5%[21] - The company’s total equity attributable to shareholders increased by 138.10% to ¥680,473,892.72 compared to the end of the previous year[3] - The company's equity attributable to shareholders reached CNY 680,473,892.72, up from CNY 285,791,619.70 in the same period last year[21] Cash Flow - Cash flow from operating activities showed a net outflow of ¥21,114,191.56 for the year-to-date period, a decline of 172.79% compared to the previous year[2] - Operating cash inflow for the period was ¥261,483,956.57, slightly down from ¥269,913,970.80 in the previous year[26] - The net cash flow from operating activities was -¥21,114,191.56, a decline from a positive cash flow of ¥29,006,195.12 in Q3 2022[26] - Net cash flow from investing activities was -261.022 million, a decline of 463.06% from -46.358 million year-on-year, mainly due to increased cash expenditures for fixed assets during the construction period of a subsidiary[11] - Net cash flow from financing activities reached 630.406 million, an increase of 1,391.48% compared to 42.267 million in the previous year, driven by funds raised from a private placement and investments received by a subsidiary[11] - Cash and cash equivalents increased to 349.727 million, up 1,210.18% from 26.693 million, influenced by the aforementioned fundraising and investment receipts[11] - Cash and cash equivalents at the end of the period increased to ¥550,437,006.29, up from ¥210,968,632.37 at the end of Q3 2022[27] Research and Development - Research and development expenses increased by 35.78% year-on-year, totaling ¥15,001,222.69 for the first nine months of 2023[9] - Research and development expenses for Q3 2023 were CNY 15,001,222.69, an increase from CNY 11,047,842.33 in Q3 2022, reflecting a growth of 35.8%[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 69,899, with the largest shareholder, Wu Jianlong, holding 28.79% of shares[12] - Wu Jianlong's pledged shares amounted to 265 million, with 167.41 million shares under lock-up until September 13, 2024[15] Changes and Plans - The company has undergone changes in its board of directors, appointing a new independent director following the resignation of a long-serving member[16] - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[24] Inventory and Receivables - The company reported a significant decrease in accounts receivable by 48.71%, amounting to ¥37,622,470.23 as of September 30, 2023[7] - Accounts receivable decreased to 37.622 million from 73.355 million, indicating a reduction in outstanding payments[19] - Inventory increased to 129.966 million from 112.271 million, reflecting a rise in stock levels[19] Operating Costs - Total operating costs for Q3 2023 were CNY 252,518,551.57, up from CNY 230,882,252.40 in the same period last year, reflecting a year-over-year increase of 9.3%[24] - The company reported a decrease in sales expenses to CNY 30,353,357.06 from CNY 42,097,607.04 in the previous year, a reduction of 28%[24]

证券代码：300111 证券简称：向日葵 公告编号：2023—064 浙江向日葵大健康科技股份有限公司 关于诉讼事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 具体内容详见公司于 2023 年 9 月 13 日在巨潮资讯网（www.cninfo.com.cn） 披露的《关于诉讼事项的进展公告》（公告编号 2023-062）。 二、案件的进展情况 近日，公司收到越城区人民法院出具的（2023）浙 0602 执恢 1294 号《结 案通知书》，申请执行人向日葵与被执行人江苏振发达成和解协议并履行完毕， 实际履行债务 3,700 万元及诉讼费、执行费，本案已全部执行完毕。 三、其他尚未披露的诉讼仲裁事项 截至本公告披露日，公司及子公司不存在应披露而尚未披露的其他诉讼、仲 裁事项。 四、对公司的影响 公司已于 2019 年度按照谨慎性原则对本次诉讼涉及的应收账款全额计提坏 账准备 47,815,503.52 元，公司合计收到的 3,700 万元将冲回部分前期计提的坏账 准备。本次诉讼和解预计增加公司 2023 年度净利润 3,700 万元（未考虑所得税 ...

证券代码：300111 证券简称：向日葵 公告编号：2023—063 浙江向日葵大健康科技股份有限公司 关于子公司终止设备购买合同暨投资项目进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江向日葵大健康科技股份有限公司（以下简称"公司"）控股子公司浙 江隆向新能源科技有限公司（以下简称"项目公司"）与深圳市捷佳伟创新能 源装备股份有限公司（以下简称"捷佳伟创"）于2023年9月28日签署了《终止 合同协议书》（以下简称"终止协议"）。具体情况如下： 一、基本情况概述 1、原合同签署情况 2023 年 4 月 14 日，项目公司与捷佳伟创签署了《购销合同书》及其附件（以 下简称"合同"或"原合同"），采购高效太阳能电池产品生产设备，合同总金 额 826,950,000 元。具体内容详见公司于 2023 年 4 月 17 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于子公司签订日常经营重大合同的公告》（公 告编号：2023-020）。 （2）捷佳伟创同意在2023年11月30日前全额退还项目公司已经支付的货款 248,085,00 ...

证券代码：300111 证券简称：向日葵 公告编号：2023—062 浙江向日葵大健康科技股份有限公司 关于诉讼事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、案件基本情况概述 2018 年，浙江向日葵大健康科技股份有限公司（以下简称"公司"）因合同 买卖纠纷向浙江省绍兴市越城区人民法院（以下简称"越城区人民法院"）对江 苏振发新能源科技发展有限公司（以下简称"江苏振发"）提起诉讼。根据越城 区人民法院（2018）浙 0602 民初 7745 号《民事判决书》：（1）被告江苏振发应 支付给公司货款 46,171,177.33 元及截至 2018 年 7 月 16 日的违约金 2,750,731.25 元，并按照中国人民银行公布的同期同类贷款基准利率支付货款自 2018 年 7 月 17 日起至判决确定履行日止的违约金（其中 3,586,448.04 元货款的利息不超过 701,052.05 元，14,631,184.06 元货款的利息不超过 722,339.03 元，27,953,545.23 元货款的利息不超过 1,586,904.95 ...

上海市锦天城律师事务所 关于浙江向日葵大健康科技股份有限公司 2023 年第二次临时股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于浙江向日葵大健康科技股份有限公司 2023 年第二次临时股东大会的 法律意见书 致：浙江向日葵大健康科技股份有限公司 根据《中华人民共和国证券法（2019 年修订）》（以下简称"《证券法》"） 《中华人民共和国公司法（2018 年修正）》（以下简称"《公司法》"）和中国 证券监督管理委员会《上市公司股东大会规则（2022 年修订）》（以下简称"《股 东大会规则》"）等法律、法规和其他有关规范性文件的要求，上海市锦天城律 师事务所（以下简称"本所"）接受浙江向日葵大健康科技股份有限公司（以下 简称"向日葵"或"公司"）的委托，指派律师参加公司 2023 年第二次临时股 东大会（以下简称"本次股东大会"或"本次会议"）。 为出具本《法律意见书》，本所声明如下： 1、本所律师仅对本次股东大会 ...

证券代码：300111 证券简称：向日葵 公告编号：2023—061 浙江向日葵大健康科技股份有限公司 关于 2023 年第二次临时股东大会决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要提示： 1、本次会议无否决或修改议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 浙江向日葵大健康科技股份有限公司（以下简称"公司"）2023年第二次临 时股东大会于2023年9月11日14:30在浙江省绍兴袍江工业区三江路公司办公楼 五楼会议室召开。本次会议采取现场投票和网络投票相结合的方式，并通过深圳 证券交易所系统和互联网投票系统提供网络投票平台。本次会议由公司董事会召 集，董事长曹阳先生主持，公司部分董事、监事、高级管理人员及公司聘请的见 证律师等相关人员通过现场或者视频方式出席或列席本次会议。本次会议的召开 符合《公司法》《公司章程》和《股东大会议事规则》的相关规定。 参加本次股东大会的股东及股东授权代表共计8人，代表股份370,686,531股， 占公司总股本1,287,210,714股的28.7977%。 ...

证券代码：300111 证券简称：向日葵 公告编号：2023—060 浙江向日葵大健康科技股份有限公司 关于诉讼事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 浙江向日葵大健康科技股份有限公司（以下简称"公司"或"向日葵"）因 不认同河南省驻马店市中级人民法院（以下简称"驻马店市中级人民法院"）(2020) 豫 17 民终 3796 号民事判决，向河南省高级人民法院（以下简称"河南高院"） 申请再审，河南高院受理公司诉河南天中百年新能源有限公司、郑州百年置业有 限公司产品责任纠纷再审案件。公司于 2021 年 12 月 9 日收到河南高院出具的 (2021)豫民申 5419 号《民事裁定书》，指令驻马店市中级人民法院再审本案，驻 马店市中级人民法院将本案发回河南省驻马店市驿城区人民法院重审，具体详见 公司分别于 2021 年 9 月 27 日、2021 年 12 月 9 日、2022 年 3 月 22 日在巨潮资 讯网（www.cninfo.com.cn）披露的《关于仲裁事项的公告》（公告编号：2021—049）、 《关于收到河南省高级人民法院 ...

证券代码：300111 证券简称：向日葵 公告编号：2023—059 浙江向日葵大健康科技股份有限公司 关于股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 浙江向日葵大健康科技股份有限公司（以下简称"公司"或"本公司"）于 近日接到股东吴建龙先生的通知，获悉吴建龙先生其所持有本公司的部分股份被 质押，具体事项如下： 一、股东股份质押的基本情况 | | 是否为控 | 本次 | 占其 | 占公 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股股东或 | 质押 | 所持 | 司总 | 是否为 | 是否为 | 质押起 | 质押到 | | 质押 | | | 第一大股 | 数量 | 股份 | 股本 | | 补充质 | | | 质权人 | | | 名称 | | | | | 限售股 | | 始日 | 期日 | | 用途 | | | 东及其一 | （股 | 比例 | 比例 | | 押 | | | | | | | 致行动人 | ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2023, representing a year-on-year increase of 15%[21]. - The net profit attributable to shareholders was RMB 200 million, up 10% compared to the same period last year[21]. - The company has set a revenue guidance of RMB 2.5 billion for the full year 2023, indicating a growth target of 20%[21]. - The company's operating revenue for the current period is ¥150,328,233.20, representing a 4.38% increase compared to ¥144,014,774.20 in the same period last year[23]. - The net profit attributable to shareholders for the current period is -¥11,643,694.34, a slight decrease of 0.36% from -¥11,601,377.33 in the previous year[23]. - The company reported a total investment of ¥270,000,000.00 during the reporting period, marking a 100% increase compared to the previous year[65]. - The company reported a total revenue of 2,015,966 yuan from a legal settlement with Jiangxi Yishite New Energy Technology Co., Ltd. for unpaid debts[112]. - The company reported a total of 69.58% of its transactions were related to daily operational activities with related parties[116]. User Engagement and Market Expansion - User data showed an increase in active users by 25%, reaching 5 million by the end of June 2023[21]. - The company plans to launch three new health products in Q4 2023, targeting a market expansion of 20% in the health sector[21]. - The company plans to expand its market presence by entering three new provinces in the second half of 2023[176]. - User data indicated a growth in active users, with a reported increase of 11% year-on-year, reaching 4.5 million active users[179]. - The company plans to expand its market presence by entering two new provinces by the end of 2023, aiming for a 15% increase in market share[179]. Research and Development - The company has allocated RMB 50 million for R&D in new technologies related to health supplements[21]. - Research and development investment amounted to RMB 8.68 million, reflecting a year-on-year increase of 16.86%[44]. - The company holds 18 drug registration certificates and has 43 patents, including 3 invention patents and 40 utility model patents, indicating a strong commitment to R&D[33]. - Research and development expenses increased by 29%, totaling 370 million yuan, focusing on new product innovations[175]. - The company has allocated 50 million CNY for research and development in new technologies, focusing on AI integration in health products[179]. Financial Position and Assets - Total assets at the end of the current period reached ¥1,457,290,145.03, a substantial increase of 136.48% from ¥616,248,544.88 at the end of the previous year[23]. - The company's cash and cash equivalents increased to ¥781,872,104.49, representing 53.65% of total assets, a significant increase of 15.81% from the previous year[57]. - The total current assets reached ¥1,052,952,371.82, up from ¥454,856,833.80, indicating an increase of 131.9%[153]. - The total assets of the company at the end of the reporting period were approximately 1.2 billion CNY, with a current ratio of 1.5[180]. Risks and Challenges - The company has identified potential risks in supply chain disruptions and regulatory changes, with strategies in place to mitigate these risks[21]. - The pharmaceutical industry is experiencing a downward trend, with a 2.9% decrease in revenue for the first half of 2023 compared to the same period in 2022[30]. - Raw material price fluctuations pose a significant risk, as the cost of key materials constitutes a large portion of production expenses[82]. - The solar energy sector is sensitive to policy changes, which could impact market demand and project timelines[85]. Corporate Governance and Legal Matters - The company has not experienced any changes in its board of directors or senior management during the reporting period[91]. - The company faced a lawsuit involving an amount of 16.46 million yuan, which was dismissed in a final ruling[108]. - The company is involved in a legal case where it is owed 60 million yuan from Henan Tianzhong Century New Energy Co., Ltd. and Zhengzhou Century Real Estate Co., Ltd., with interest calculated at four times the benchmark rate since January 2014[109]. - The company has a pending claim for 46,171,177.33 yuan from Jiangsu Zhenfa New Energy Co., Ltd. regarding a sales contract dispute[110]. Shareholder Information - The total number of shareholders at the end of the reporting period is 69,705[138]. - The largest shareholder, Wu Jianlong, holds 28.79% of the shares, totaling 370,630,131 shares, with a pledge of 228,000,000 shares[138]. - The company did not distribute cash dividends or bonus shares for the first half of 2023[92]. Environmental and Social Responsibility - The company has invested a total of 820,000 yuan in environmental protection measures in the first half of 2023[99]. - The company has a valid pollution discharge permit effective from October 28, 2022, to October 27, 2027[96]. - There were no significant environmental violations or penalties reported during the reporting period[100].

证券代码：300111 证券简称：向日葵 公告编号：2023—058 浙江向日葵大健康科技股份有限公司 关于公司召开2023年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2023年第二次临时股东大会 2、股东大会的召集人：本次股东大会由董事会召集，经公司第五届董事会 第二十二次会议决议通过。 3、会议召开的合法、合规性：本次股东大会的召开符合有关法律、行政法 规、部门规章、规范性文件和公司章程的相关规定。 4、现场会议召开时间：2023年9月11日（星期一）14:30 网络投票时间：通过深圳证券交易所交易系统进行投票的具体时间为：2023 年9月11日9:15至9:25，9:30至11:30，13:00至15:00；通过深圳证券交易所互联网 投票系统投票的具体时间为：2023年9月11日9:15至2023年9月11日15:00期间的任 意时间。 （2）公司董事、监事和高级管理人员。 （3）公司聘请的律师。 8、会议召开地点：浙江省绍兴市袍江工业区三江路浙江向日葵大健康科技 股份有限公司办公 ...